Assenagon Asset Management’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Assenagon Asset Management’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-178,622	Closed	-$4.41M	–	1343
2020 Q4	$4.41M	Sell	178,622 -331,878	-65%	-$11M	0.02%	373
2020 Q3	$21.2M	Buy	+510,500	New	+$23.5M	0.12%	124
2020 Q1	–	Sell	-9,616	Closed	-$1.19M	–	1043
2019 Q4	$1.19M	Buy	+9,616	New	+$861K	0.01%	546
2019 Q1	–	Sell	-22,180	Closed	-$2.24M	–	1155
2018 Q4	$2.24M	Buy	+22,180	New	+$2.3M	0.03%	416

Other funds holding ICPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Assenagon Asset Management's ICPT Position: Q1 2021 in Review

Assenagon Asset Management sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q1 2021, closing a stake of 178,622 shares — an estimated $4.41M sold.

Assenagon Asset Management first reported a position in ICPT in Q4 2018 and held it in 4 quarters. The position peaked at $21.2M in Q3 2020. 151 funds tracked by Wall St. Rank hold ICPT as of Q1 2021.

Assenagon Asset Management reported no remaining Intercept Pharmaceuticals, Inc. position as of Q1 2021 after selling out during the quarter.
Assenagon Asset Management sold 178,622 Intercept Pharmaceuticals, Inc. shares in Q1 2021, an estimated $4.41M.
Assenagon Asset Management first reported a position in Intercept Pharmaceuticals, Inc. in Q4 2018 and held it in 4 quarters.
Assenagon Asset Management's Intercept Pharmaceuticals, Inc. position peaked at $21.2M in Q3 2020.
151 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q1 2021.

Based on Assenagon Asset Management's 13F filing for Q1 2021, filed 26 Apr 2021.